This paper is only available as a PDF. To read, Please Download here.
Abstract
Bradykinin (BK) and [des-Arg9]-bradykinin (−9BK) concentrations in blood and urine samples from 18 normotensive
subjects and 23 patients with low-renin essential hypertension were determined by
radioimmunoassay. BK and −9BK levels in venous blood from normotensive subjects were
67.1 ± 60.8 pg/ml and 204.1 ± 44.5 (mean ± S.D.), respectively, and levels in urine
from normotensive subjects were 5.3 ± 5.3 ng/ml and 1.6 ± 1.2, respectively. The blood
and urinary levels of BK and −9BK in low-renin essential hypertensives were not significantly
different from those of normotensives and did not change when the hypertensives were
treated with the new orally active angiotensin I-converting enzyme (ACE) inhibitor,
enalapril (MK421). It has been proposed that BK levels do not change with ACE inhibition
because under these conditions BK might be metabolized to −9BK by kininase I. Since
−9BK levels did not increase with MK421 treatment, this possibility can be excluded.
The absence of elevations in blood and urine BK and −9BK after administration of MK421
does not support an involvement of kinins in the mechanism of antihypertensive action
of MK421 in these patients. On the basis of the data, it is not possible to exclude
such an involvement, however, because local changes in kinin concentrations could
occur that are not reflected by changes in circulating or urinary kinin levels.
Abbreviations:
(ACE) (angiotensin I-converting enzyme), (BK) (bradykinin), (−9BK) ([des-Arg9]-bradykinin), (B1) (receptors for −9BK), (B2) (receptors for BK)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Translational ResearchAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.Science. 1977; 196: 441
- A new class of angiotensin-converting enzyme inhibitors.Nature. 1980; 228: 280
- Converting enzyme inhibition in essential hypertension: the hypotensive response does not reflect only reduced angiotensin II formation.Hypertension. 1979; 1: 106
- Conversion of angiotensin I to angiotensin II.Am J Med. 1976; 60: 749
- Differences in response to the peptidyldipeptide hydrolase inhibitors SQ 20881 and SQ 14225 in normal-renin essential hypertension.Hypertension. 1980; 2: 604
- Endocrine profile in the long-term phase of converting enzyme inhibition.Clin Pharmacol Ther. 1980; 28: 499
- Sodium intake and renal responses to captopril in normal man and in essential hypertension.Kidney Int. 1981; 20: 240
- Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension.Hypertension. 1981; 3: 168
- Increased glomerular fiitration rate after converting-enzyme inhibition in essential hypertension.N Engl J Med. 1979; 301: 9
- Comparison of the hormonal effects of captopril (SQ 14225) and hydrochlorothiazide in the treatment of essential hypertension.Med J Aust Spec. 1979; : 17
- The effect of converting enzyme inhibition with SQ 20881 on plasma and urinary kinins, prostaglandin E, and angiotensin II in hypertensive man.Hypertension. 1979; 1: 416
- Acute changes in blood pressure and vasoactive hormones after captopril in hypertensive patients.Clin Exp Pharmacol Physiol. 1980; 7: 487
- Acute effects of captopril on blood pressure and circulating hormone levels in salt-replete and depleted normal subjects and essential hypertensive patients.Clin Sci. 1981; 61: 75
- The effect of the converting enzyme inhibitor SQ 20881 on kinins, renin-angiotensin-aldosterone and catecholamines in relation to blood pressure in hypertensive patients.Acta Med Scand. 1978; 204: 497
- An enzyme in human blood plasma that inactivates bradykinin and kallidins.Biochem Pharmacol. 1962; 11: 585
- The degradation of bradykinin (BK) and of des-Arg9-BK in plasma.Can J Physiol Pharmacol. 1981; 59: 131
- Cardiovascular actions of kinins in the rabbit.Can J Physiol Pharmacol. 1979; 57: 78
- Chemistry and biologic activity of peptides related to bradykinin.in: ed. 2. Handbook of Experimental Pharmacology. Vol. XXV. Springer-Verlag, New York1979: 227 (Suppl.)
- Pharmacology of bradykinin and related kinins.Pharmacol Rev. 1980; 32: 1
- Receptors for bradykinin in rabbit aortae.Can J Physiol Pharmacol. 1977; 55: 855
- Enalapril in low-renin essential hypertension.Clin Pharmacol Ther. 1983; 34: 297
- Effects of pH and enzyme inhibitors on apparent generation of angiotensin I in human plasma.J Clin Endocrinol Metab. 1974; 39: 965
- Application of a radioimmunoassay for angiotensin I to the physiologic measurement of plasma renin activity in normal human subjects: renin activity by angiotensin I radioimmunoassay.J Clin Endocrinol Metab. 1969; 29: 1349
- Determination of blood kinin levels by radioimmunoassay.Biochem Pharmacol. 1972; 21: 2727
- Development of a radioimmunoassay for [des-Arg9]-bradykinin.Biochem Pharmacol. 1983; 32: 337
- Aspects of bradykinin radioimmunoassay.J Immunol Methods. 1978; 19: 243
- Blood kinins, their concentration in normal subjects and in patients with congenital deficiency in plasma prekallikrein and kininogen.J Lab Clin Med. 1982; 100: 81
- Determination of human urinary kinin levels by radioimmunoassay using a tyrosine analogue of bradykinin.Biochem Pharmacol. 1971; 20: 969
- Kinins in relation to kallikrein activity, kininogen, electrolytes, aldosterone and catecholamines in urine from normal individuals.Acta Physiol Scand. 1980; 110: 307
- Carboxypeptidase-type kininase of human kidney and urine.in: ed. 2. Proc Soc Exp Biol Med. 165. 1980: 6
Article info
Publication history
Accepted:
June 24,
1983
Received:
January 3,
1983
Footnotes
☆This work was supported by a grant-in-aid from the American Heart Association, Indiana Affiliate, Inc; General Clinical Research Center of the University of Alabama in Birmingham (DRR-RB-32); and by grants HL 22544 and HL 25451 from the United States Public Health Service, National Institutes of Health.
Identification
Copyright
© 1983 Published by Elsevier Inc.
